Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.

In a prespecified participant-level pooled analysis of three trials (FINE-HEART; 18,991 participants), finerenone reduced all-cause mortality, heart failure hospitalization, and the composite kidney outcome, though the reduction in cardiovascular death did not reach statistical significance.